John McDonough

John McDonough is a member of the Board of Directors at Solace Therapeutics and BioPorto Diagnostics. He is responsible for raising over $500 million of public and private capital creating over $6 billion of market value for 5 different companies over the past 30 years.

Previously, Mr. McDonough served in CEO and senior executive management roles in both private and public companies, including successfully leading two IPO’s, serving as CEO of four companies including two established public companies, and as CEO or senior management executive at four start-up companies. Mr. McDonough has led the acquisition of five companies, led merger or acquisition of business with three different companies, and was Board member of two companies successfully acquired by industry leaders.

From 2007 through January 2020, Mr. McDonough was Founding President and CEO of T2 Biosystems where he developed and manufactured next-generation diagnostics to get patients on the right therapy faster, starting with sepsis.